This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: Opportunities for Participation

SSC Subcommittee Invites Participation in Registry on Pregnancy and COVID-19 Coagulopathy

Friday, May 29, 2020   (0 Comments)
Share |

The extent and frequency of coagulation abnormalities in COVID-19 during pregnancy are currently unknown. The impact on fetal and maternal outcomes and the use and safety of antiviral therapies LMWH, corticosteroids in the context of COVID-19 and pregnancy are also unknown.

The SSC Subcommittee for Women's Heath Issues in Thrombosis and Hemostasis developed this registry with the following objectives:

  1. To examine coagulopathy and VTE events in COVID-19 affected pregnancies and their potential link to disease severity. To assess effects of COVID-19 related coagulopathy on maternal and fetal/neonatal outcomes
  2. To study the hemostatic parameters in women with COVID-19, during each trimester of pregnancy and the postpartum period
  3. To evaluate the use/effects of therapies such as LMWH, Steroids for acceleration of fetal lung maturity, antibiotics, and antivirals

The registry is open for participation by Physicians/Health Care Providers worldwide. Subject to contribution, participants will be recognized in future publications. All patient-related data are non-identifiable.

Inclusion Criteria: All pregnant individuals with a confirmed COVID-19 infection.

Knowledge of the incidence of COVID-19-related coagulopathy and clinical and laboratory parameters with prognostic utility can be extremely valuable in managing pregnant women with COVID-19. This can determine the best treatment options, balancing maternal and fetal/neonatal risks and benefits, and avoiding unnecessary interventions.

Thank you very much for your consideration to provide critically useful data for the care of future patients.

Please participate here

Project leads: Drs. Maha Othman and A. Kinga Malinowski

Project coordinator: Dr. Sajida Kazi, sajida.kazi@doctors.net.uk

On behalf of the ISTH SSC for Women's Health Issues in Thrombosis & Haemostasis.


Membership Management Software Powered by YourMembership  ::  Legal